EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
WALTHAM, Mass., July 1, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under
Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize
Southampton, UK – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and small molecule